05:36 PM EDT, 10/21/2024 (MT Newswires) -- Revolution Medicines ( RVMD ) dosed the first patient in its phase 3 study evaluating RMC-6236 as a potential treatment for previously treated, metastatic pancreatic ductal adenocarcinoma.

The open-label study will evaluate the safety and efficacy of RMC-6236 as a monotherapy against standard of care chemotherapy, Revolution Medicines ( RVMD ) said Monday in a statement.

Shares of the company rose 2.5% in recent after-hours activity.

Price: 48.92, Change: +1.17, Percent Change: +2.45